NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

 

• Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study
• Additionally, milestone payments and double-digit royalties on annual net sales
• The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025

https://www.prnewswire.com/news-releases/neurosense-therapeutics-enters-binding-term-sheet-to-advance-primec-for-als-302338331.html